### Etoposide

**Indication**
Other specified malignant neoplasms of the ovary  
**ICD11 code:** 2D23.Y

<table>
<thead>
<tr>
<th>INN</th>
<th>Etoposide</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medicine type</td>
<td>Chemical agent</td>
</tr>
<tr>
<td>List type</td>
<td>Complementary</td>
</tr>
</tbody>
</table>
| Formulations | Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule  
Oral > Solid: 100 mg capsule; 50 mg capsule |
| EML status history | First added in 2015 (TRS 994)  
Changed in 2019 (TRS 1021) |
| Sex | All |
| Age | Also recommended for children |
| Therapeutic alternatives | The recommendation is for this specific medicine |
| Patent information | Patents have expired in most jurisdictions  
[Read more about patents.](#) |

**Tags**
- Cancer

**Wikipedia**
- Etoposide

**DrugBank**
- Etoposide

---

**Summary of evidence and Expert Committee recommendations**

The Expert Committee recommended the addition of 50 mg strength formulation of etoposide capsules to the EML and EMLc.